Aspirin May Cut Risk of Certain Cancers December 7, 2010Posted by Metabiological in Longevity.
Tags: aspirin, cancer, longevity, science
We’ve known for awhile now that taking a low-dose of aspirin cut cut the risk of heart disease but according to some new studies it may cut the risk of many cancers as well.
The research involved in the current review had been conducted for an average period of four to eight years. The patients (some of whom had been given a low-dose aspirin regimen, while others were not) were tracked for up to 20 years after. The authors determined that while the studies were still underway, overall cancer death risk plummeted by 21 percent among those taking low-dose aspirin. But the long-term benefits on some specific cancers began to show five years after the studies ended. At five years out, death due to gastrointestinal cancers had sunk by 54 percent among those patients taking low-dose aspirin. The protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road. Twenty years after first beginning a low-dose aspirin program, death risk dropped by 10 percent among prostate cancer patients; 30 percent among lung cancer patients (although only those with adenocarcinomas, the type typically seen in nonsmokers); 40 percent among colorectal cancer patients; and 60 percent among esophageal cancer patients.
Those are some pretty impressive numbers. That being said before everyone runs out to pick up a bottle of Bayer it must be noted that taking low-doses of aspirin has also been found to increase risk of stroke. Weigh the risks for yourself and as always use in the proper amount.